Citius Oncology launches LYMPHIR, first commercial product, for CTCL

CITIUS ONCOLOGY, INC.

LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.
Phase 3 pivotal study: 36.2% ORR, median time to response 1.4 months, no cumulative toxicity.
Entering U.S. market estimated >$400M; permanent J-code J9161 and NCCN Category 2A inclusion.
Ex-U.S. distribution pact with Integris Pharma for 12 Southern European/Balkan markets.
Company holds exclusive rights to all markets except India, Japan, and parts of Asia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.